1.Pharmacokinetics of aristolochic acid A in Radix Aristolochiae and Guanxinsuhe Capsule
Baoping TIAN ; Lantong ZHANG ; Zhifang YUAN ; Weina LIU ; Hongju LIU
Chinese Traditional and Herbal Drugs 2005;36(11):1671-1674
Objective To study the pharmacokinetics of aristolochic acid A in Radix Aristolochiae and the compound preparation of Guanxinsuhe Capsule in mice in vivo after single-dose oral administration and observe the difference of aristolochic acid A absorption and distribution. Methods Aristolochic acid A assay was performed by RP-HPLC on a Waters apparatus with a DiamonsilTM C18 column (250 mm × 4.6mm, 5 μm), a mobil phase: a mixture of methanol-water-acetic acid (72: 27 : 1), flow rate: 1.0 mL/min, detection wavelength: 315 nm, and column temperature: 20 ℃. Results Mice were given Radix Aristolochiae and Guanxinsuhe Capsule by ig at the same level of 2. 5 mg/kg of aristolochic acid A, respectively, which were suspended in 0. 3% CMC-Na solution. Plasma concentrations were determined by RPHPLC. After single-dose ig administration of Radix Aristolochiae or Guanxinsuhe Capsule to mice, the mean plasma concentration-time courses of aristolochic acid A obtained fitted the one-compartment model.The main pharmacokinetic parameters of aristolochic acid A in Radix Aristolochiae, t1/2ka, t1/2 ke, tmax,AUC, Cmax are 5. 103 min, 43. 63 min, 17.89 min, 80. 45 (μg · min)/mL, and 0. 916 8 μg/mL; the rela tive pharmacokinetic parameters in Guanxinsuhe Capsule are 5. 294 min, 43.50 min, 18. 32 min, 33.08(μg · min)/mL, and 0. 381 8 μg/mL. Conclusion The Cmax of aristolochic acid A in Guanxinsuhe Capsule is significantly less than that in Radix Aristolochiae, which indicates that the compound compability could decrease the absorption of aristolochiae acid A.
2.Protective Mechanism of Salvianolic Acid B on Myocardial Ischemia-reperfusion Injury of Rats
Liang ZHANG ; Dongping YUAN ; Li XU ; Baoping JIANG ; Taihui FANG
Traditional Chinese Drug Research & Clinical Pharmacology 2000;0(06):-
Objective To investigate the protective mechanism of Salvianolic acid B (Sal B) on experimental in-vivo myocardial ischemia-reperfusion injury (MIRI)in rats. Methods Rats model of myocardial ischemia-reperfusion injury was induced by ischemia for 60 min and then reperfusion for 60 min. After treatment,endothelin (ET) levels in plasma and the homogenate of myocardial tissue,and serum levels of nitric oxide (NO) and NO synthase were measured. Meanwhile,the pathological changes of myocardial tissue were also observed. Results Compared with the model group,middle-dose and high-dose Sal B could depress the ET levels in the plasma and the myocardial tissue,and increase the content of serum NO and NOS (P
3.Research progress of sarcolipin-a new regulatory protein of sarcoplasmic reticulum Ca2+ ATPase.
Baoping YUAN ; Rong LU ; Yanpin GU ; Yueling LIAO ; Hongchang WEI
Journal of Central South University(Medical Sciences) 2012;37(3):316-319
Sarcolipin (SLN) is a 3 kD membrane protein found in sarcoplasmic reticulum (SR). It has 31 amino acid residues; SLN and phopholamban (PLB) are belong to the same protein family, so they have similar physiological functions. SLN inhibits sarcoplasmic reticulum Ca(2+) ATPase (SERCA) activity and reduces its affinity of Ca(2+), resulting in dysfunction of myocardial contraction and heart failure. However, much remains to be elucidated. SLN independently or in conjunction with PLB affects SERCA activity, imbalancing intracellular calcium homeostasis, and reducing myocardial contractivity; these effects promote the development of heart failure.
Animals
;
Calcium-Binding Proteins
;
physiology
;
Heart Failure
;
physiopathology
;
Humans
;
Muscle Proteins
;
metabolism
;
physiology
;
Myocardial Contraction
;
physiology
;
Proteolipids
;
metabolism
;
physiology
;
Sarcoplasmic Reticulum
;
metabolism
;
Sarcoplasmic Reticulum Calcium-Transporting ATPases
;
antagonists & inhibitors
;
metabolism
4.Expert consensus on nucleic acid amplification test of respiratory pathogens in children
Zhengde XIE ; Jikui DENG ; Lili REN ; Yan ZHANG ; Xiangpeng CHEN ; Hailin ZHANG ; Linqing ZHAO ; Baoping XU ; Lili ZHONG ; Qiang QIN ; Gen LU ; Yuejie ZHENG ; Deyu ZHAO ; Yunxiao SHANG ; Ling CAO ; Zhimin CHEN ; Yong YIN ; Hanmin LIU ; Adong SHEN ; Binwu YING ; Zhou FU ; Changchong LI ; Yuan QIAN ; Wenbo XU ; Jianwei WANG ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2022;37(5):321-332
Acute respiratory tract infection is the most common infectious disease in children, which seriously threatens children′s health.Rapid and accurate etiological diagnosis is of great significance for the clinical treatment and control of these diseases.Pathogen nucleic acid test was applied and became the main method of respiratory tract infection diagnosis for its high sensitivity and specificity.To regulate the application of pathogen nucleic acid amplification test in respiratory tract infection in children, improve the diagnosis level, expert consensus on nucleic acid amplification test of respiratory pathogens in children was prepared to guide the application and promote pathogens diagnosis ability.
5. Guidance on strengthening the management processes of children′s fever in outpatient department during the novel coronavirus pneumonia epidemic period (First Edition)
Guocheng ZHANG ; Xiaoning CHENG ; Hui DING ; Zhaoling SHI ; Ruying LI ; Zhou FU ; Qiang CHEN ; Dongchi ZHAO ; Runming JIN ; Guoming NIE ; Jirong LU ; Changshan LIU ; Deyu ZHAO ; Jiahua PAN ; Zhichun FENG ; Yuan SHI ; Zhengkun XIA ; Chengzhong ZHENG ; Jinjin JIANG ; Junxia WANG ; Yuejie ZHENG ; Yunxiao SHANG ; Wei XIANG ; Baoping XU ; Kunling SHEN ; Tianyou WANG ; Yonghong YANG ; Quan LU
Chinese Journal of Applied Clinical Pediatrics 2020;35(2):97-104
Novel Coronavirus Pneumonia (NCP) is a class B infectious disease, which is prevented and controlled according to class A infectious diseases. Recently, children′s NCP cases have gradually increased, and children′s fever outpatient department has become the first strategic pass to stop the epidemic. Strengthening the management of the fever diagnosis process is very important for early detection of suspected children, early isolation, early treatment and prevention of cross-infection. This article proposes prevention and control strategies for fever diagnosis, optimizes processes, prevents cross-infection, health protection and disinfection of medical staff, based on the relevant diagnosis, treatment, prevention and control programs of the National Health and Health Commission and on the diagnosis and treatment experience of experts in various provinces and cities. The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children′s fever in outpatient department during the novel coronavirus pneumonia epidemic period.